Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 4/2018

01-04-2018 | Head and Neck Oncology

A Clinical Trial of Combination Neoadjuvant Chemotherapy and Transoral Robotic Surgery in Patients with T3 and T4 Laryngo-Hypopharyngeal Cancer

Authors: Young Min Park, MD, PhD, Ki Chang Keum, MD, PhD, Hye Ryun Kim, MD, PhD, Byoung Chul Cho, MD, PhD, Da Hee Kim, MD, Nam Hoon Cho, MD, PhD, Se-Heon Kim, MD, PhD

Published in: Annals of Surgical Oncology | Issue 4/2018

Login to get access

Abstract

Background

We conducted a prospective clinical trial of combination neoadjuvant chemotherapy, transoral robotic surgery (TORS), and customized adjuvant therapy in patients with locally advanced laryngo-hypopharyngeal cancer.

Methods

Between September 2008 and August 2016, 35 patients were enrolled in this clinical trial.

Results

Twenty patients had hypopharyngeal cancer and 15 had laryngeal cancer. Twenty-nine patients (82.9%) had T3 disease and six patients (17.1%) had T4 disease, while 12 patients (34.3%) had stage III disease and 23 patients (65.7%) had stage IV disease. The 3-year disease-specific survival rate was 82.4% and the 3-year disease-free survival rate was 69.48%. Decannulation was successful in 31 of 34 patients at an average of 18 days postoperatively. Among all patients, 83% exhibited a favorable subjective swallowing status, while five patients (14.4%) became dependent on feeding tubes.

Conclusions

Neoadjuvant chemotherapy combined with TORS and customized adjuvant therapy, based on detailed pathological information, afforded favorable oncological outcomes and preserved organ functionalities in T3–T4 laryngo-hypopharyngeal cancer.
Appendix
Available only for authorised users
Literature
1.
Brizel DM, Albers ME, Fisher SR, et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 1998;338:1798–804.CrossRefPubMed
2.
Wendt TG, Grabenbauer GG, Rödel CM, et al. Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study. J Clin Oncol 1998;16:1318–24.CrossRefPubMed
3.
Calais G, Alfonsi M, Bardet E, et al. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst 1999;91:2081–6.CrossRefPubMed
4.
Adelstein DJ, Lavertu P, Saxton JP, et al. Mature results of a phase III randomized trial comparing concurrent chemoradiotherapy with radiation therapy alone in patients with stage III and IV squamous cell carcinoma of the head and neck. Cancer 2000;88:876–83.CrossRefPubMed
5.
Olmi P, Crispino S, Fallai C, et al. Locoregionally advanced carcinoma of the oropharynx: conventional radiotherapy vs. accelerated hyperfractionated radiotherapy vs. concomitant radiotherapy and chemotherapy–a multicenter randomized trial. Int J Radiat Oncol Biol Phys 2003;55:78–92.CrossRefPubMed
6.
Staar S, Rudat V, Stuetzer H, et al. Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy–results of a multicentric randomized German trial in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 2001;50:1161–71.CrossRefPubMed
7.
Budach V, Stuschke M, Budach W, et al. Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: final results of the radiotherapy cooperative clinical trials group of the German Cancer Society 95-06 Prospective Randomized Trial. J Clin Oncol 2005;23:1125–35.CrossRefPubMed
8.
Bensadoun RJ, Bénézery K, Dassonville O, et al. French multicenter phase III randomized study testing concurrent twice-a-day radiotherapy and cisplatin/5-fluorouracil chemotherapy (BiRCF) in unresectable pharyngeal carcinoma: Results at 2 years (FNCLCC-GORTEC). Int J Radiat Oncol Biol Phys 2006;64:983–94.CrossRefPubMed
9.
Henk JM. Controlled trials of synchronous chemotherapy with radiotherapy in head and neck cancer: overview of radiation morbidity. Clin Oncol (R Coll Radiol) 1997;9:308–12.CrossRef
10.
Trotti A, Bellm LA, Epstein JB, et al. Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review. Radiother Oncol 2003;66:253–62.CrossRefPubMed
11.
Machtay M, Moughan J, Trotti A, et al. Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. J Clin Oncol 2008;26:3582–9.CrossRefPubMedPubMedCentral
12.
Weinstein GS, O’Malley BW Jr, Hockstein NG. Transoral robotic surgery: supraglottic laryngectomy in a canine model. Laryngoscope 2005;115:1315–9.CrossRefPubMed
13.
Park YM, Kim WS, De Virgilio A, Lee SY, Seol JH, Kim SH. Transoral robotic surgery for hypopharyngeal squamous cell carcinoma: 3-year oncologic and functional analysis. Oral Oncol 2012;48:560–6.CrossRefPubMed
14.
Salassa JR. A functional outcome swallowing scale for staging oropharyngeal dysphagia. Dig Dis 1999;17:230–4.CrossRefPubMed
15.
Park YM, Lee SY, Park SW, Kim SH. Role of cancer stem cell in radioresistant head and neck cancer. Auris Nasus Larynx 2016;43:556–61.CrossRefPubMed
16.
Shirai K, Saitoh JI, Musha A, et al. Clinical outcomes of definitive and postoperative radiotherapy for Stage I-IVB hypopharyngeal cancer. Anticancer Res 2016;36:6571–8.CrossRefPubMed
17.
Yang L, Chen WK, Guo ZM, et al. Long-term survival of induction chemotherapy plus surgery and postoperative radiotherapy in patients with stage IV hypopharyngeal cancer. Anticancer Drugs 2010;21:872–6.CrossRefPubMed
18.
Lee MS, Ho HC, Hsiao SH, Hwang JH, Lee CC, Hung SK. Treatment results and prognostic factors in locally advanced hypopharyngeal cancer. Acta Otolaryngol 2008;128:103–9.CrossRefPubMed
19.
Kraus DH, Zelefsky MJ, Brock HA, Huo J, Harrison LB, Shah JP. Combined surgery and radiation therapy for squamous cell carcinoma of the hypopharynx. Otolaryngol Head Neck Surg 1997;116:637–41.CrossRef
20.
Kajanti M, Mantyla M. Carcinoma of the hypopharynx: a retrospective analysis of the treatment results over a 25-year period. Acta Oncol 1990;29:903–07.CrossRefPubMed
21.
Ho CM, Lam KH, Wei WI, Yuen PW, Lam LK. Squamous cell carcinoma of the hypopharynx: analysis of treatment results. Head Neck 1993;15:405–12.CrossRefPubMed
22.
Shirinian MH, Weber RS, Lippman SM, et al. Laryngeal preservation by induction chemotherapy plus radiotherapy in locally advanced head and neck cancer: the M.D. Anderson Cancer Center experience. Head Neck 1994;16:39–44.CrossRefPubMed
23.
Lefebvre JL. Larynx preservation: the discussion is not closed. Otolaryngol Head Neck Surg 1998;118:389–393.CrossRefPubMed
24.
25.
Beauvillain C, Mahé M, Bourdin S, et al. Final results of a randomized trial comparing chemotherapy plus radiotherapy with chemotherapy plus surgery plus radiotherapy in locally advanced resectable hypopharyngeal carcinomas. Laryngoscope 1997;107:648–53.CrossRefPubMed
26.
Harris BN, Biron VL, Donald P, et al. Primary surgery vs chemoradiation treatment of advanced-stage hypopharyngeal squamous cell carcinoma. JAMA Otolaryngol Head Neck Surg 2015;141:636–40.CrossRefPubMed
Metadata
Title
A Clinical Trial of Combination Neoadjuvant Chemotherapy and Transoral Robotic Surgery in Patients with T3 and T4 Laryngo-Hypopharyngeal Cancer
Authors
Young Min Park, MD, PhD
Ki Chang Keum, MD, PhD
Hye Ryun Kim, MD, PhD
Byoung Chul Cho, MD, PhD
Da Hee Kim, MD
Nam Hoon Cho, MD, PhD
Se-Heon Kim, MD, PhD
Publication date
01-04-2018
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 4/2018
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-017-6208-5

Other articles of this Issue 4/2018

Annals of Surgical Oncology 4/2018 Go to the issue

Hepatobiliary Tumors

Liver Transplantation is Equally Effective as a Salvage Therapy for Patients with Hepatocellular Carcinoma Recurrence Following Radiofrequency Ablation or Liver Resection with Curative Intent

Thoracic Oncology

Air Bubble Sign: A New Screening Method for Anastomotic Leakage After Esophagectomy for Esophageal Cancer

Pancreatic Tumors

Microscopic Venous Invasion in Pancreatic Cancer

Pancreatic Tumors

Gemcitabine and Taxane Adjuvant Therapy with Chemoradiation in Resected Pancreatic Cancer: A Novel Strategy for Improved Survival?

Endocrine Tumors

Cost Effectiveness of Routine Laryngoscopy in the Surgical Treatment of Differentiated Thyroid Cancer

Melanomas

Steps to Getting Your Manuscript Published in a High-Quality Medical Journal